Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MajesTEC-7: Teclistamab or Talquetamab + Daratumumab + Lenalidomide in Newly Diagnosed Multiple Myeloma
NCT05552222Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Apr 2031
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of teclistamab, talquetamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Oct 2022; status: recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05552222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552222.